Maze Therapeutics, Inc. Common Stock MAZE Balance Sheet Statement
| FY'25 | ||
|---|---|---|
| $189.25M-3.8% | ||
| $152.67M— | ||
| —— | ||
| $349.72M+73.4% | ||
| $5.04M-24.4% | ||
| $397.13M+65.1% | ||
| $10.78M+1,080% | ||
| —— | ||
| $22.56M+9.1% | ||
| —— | ||
| $42.16M-3.4% | ||
| $49K+2,350% | ||
| -$489.55M-36.6% | ||
| $354.97M+214% | ||
| $397.13M+65.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Maze Therapeutics, Inc. Common Stock's total assets?
- Maze Therapeutics, Inc. Common Stock (MAZE) holds $419.7M in total assets, up 26.1% year over year.
- How much debt does Maze Therapeutics, Inc. Common Stock have?
- Maze Therapeutics, Inc. Common Stock carries $61.2M in total debt against $341.7M of shareholders' equity, a debt-to-equity ratio of 0.18.
- How much cash does Maze Therapeutics, Inc. Common Stock have?
- Maze Therapeutics, Inc. Common Stock holds $198.8M in cash and equivalents.
- Can Maze Therapeutics, Inc. Common Stock cover its short-term obligations?
- Its current ratio is 17.88 — current assets exceed current liabilities.
- Where does Maze Therapeutics, Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
